Skip to main content

13 - References

References

578 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 5 References

  1. Colom F, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose ­disease is in remission. Arch Gen Psychiatry 2003; 60:­402–­407.
  2. Young RC, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:­429–­435.
  3. Gracious BL, et al. Discriminative validity of a parent version of the Young Mania Rating Scale. J Am Acad Child Adolesc Psychiatry 2002; 41:­1350–­1359.
  4. Poznanski EO, et al. Preliminary studies of the reliability and validity of the children’s depression rating scale. J Am Acad Child Psychiatry 1984; 23:­191–­197.
  5. Spearing MK, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-­BP. Psychiatry Res 1997; 73:­159–­171.
  6. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical Guidance [CG185]. 2014 (last updated December 2023); https://www.nice.org.uk/guidance/cg185.
  7. Correll CU, et al. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-­controlled trials. Bipolar Disord 2010; 12:­116–­141.
  8. Duffy A, et al. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry 2002; 63:­1171–­1178.
  9. Geddes JR, et al. Treatment of bipolar disorder. Lancet 2013; 381:­1672–­1682.
  10. Diaz-­Caneja CM, et al. Practitioner review: long-­term pharmacological treatment of pediatric bipolar disorder. J Child Psychol Psychiatry 2014; 55:­959–­980.
  11. Pacchiarotti I, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170:­1249–­1262.
  12. DelBello MP, et al. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-­blind, placebo-­controlled study. J Am Acad Child Adolesc Psychiatry 2017; 56:­1015–­1025.
  13. Singh MK, et al. Lurasidone in children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-­controlled trial. J Child Adolesc Psychopharmacol 2020; 30:­590–­598.
  14. DelBello MP, et al. Tolerability, safety, and effectiveness of two years treatment with lurasidone in children and adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2021; 31:­494–­503.
  15. Goldsmith M, et al. Antidepressants and psychostimulants in pediatric populations: is there an association with mania? Paediatr Drugs 2011; 13:­225–­243.
  16. Dickstein DP, et al. Randomized double-­blind placebo-­controlled trial of lithium in youths with severe mood dysregulation. J Child Adolesc Psychopharmacol 2009; 19:­61–­73.
  17. Vidal-­Ribas P, et al. The status of irritability in psychiatry: a conceptual and quantitative review. J Am Acad Child Adolesc Psychiatry 2016; 55:­556–­570.
  18. Miklowitz DJ. Evidence-­based family interventions for adolescents and young adults with bipolar disorder. J Clin Psychiatry 2016; 77 Suppl E1:e5.
  19. Wozniak J, et al. A randomized, double-­blind, controlled clinical trial of omega-­3 fatty acids and inositol as monotherapies and in combination for the treatment of pediatric bipolar spectrum disorder in children age 5-­12. Psychopharmacol Bull 2022; 52:­31–­51.
  20. Riccobene T, et al. Pharmacokinetics, safety, and tolerability of cariprazine in pediatric patients with bipolar I disorder or schizophrenia. J Child Adolesc Psychopharmacol 2022; 32:­434–­443.
  21. Wall CA, et al. Magnetic resonance imaging-­guided, open-­label, high-­frequency repetitive transcranial magnetic stimulation for adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2016; 26:­582–­589.
  22. Pathak V, et al. Efficacy of adjunctive high frequency repetitive transcranial magnetic stimulation of right prefrontal cortex in adolescent mania: a randomized sham-­controlled study. Clin Psychopharmacol Neurosci 2015; 13:­245–­249.
  23. Moghaddam HS, et al. Efficacy of melatonin as an adjunct in the treatment of acute mania: a double-­blind and placebo-­controlled trial. Int Clin Psychopharmacol 2020; 35:­81–­88.
  24. Grant B, et al. Using lithium in children and adolescents with bipolar disorder: efficacy, tolerability, and practical considerations. Paediatr Drugs 2018; 20:­303–­314.
  25. Geller B, et al. Double-­blind and placebo-­controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998; 37:­171–­178.
  26. Kafantaris V, et al. Lithium treatment of acute mania in adolescents: a placebo-­controlled discontinuation study. J Am Acad Child Adolesc Psychiatry 2004; 43:­984–­993.
  27. Findling RL, et  al. Lithium in the acute treatment of bipolar I disorder: a double-­blind, placebo-­controlled study. Pediatrics 2015; 136:­885–­894.
  28. Findling RL, et al. Double-­blind 18-­month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44:­409–­417.
  29. Duffy A, et al. Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: a systematic review: a report from the ISBD-­IGSLi joint task force on lithium treatment. Bipolar Disord 2018; 20:­583–­593.
  30. Patino LR, et al. A randomized, double-­blind, controlled trial of lithium versus quetiapine for the treatment of acute mania in youth with early course bipolar disorder. J Child Adolesc Psychopharmacol 2021; 31:­485–­493.
  31. Findling RL, et al. Lithium for the maintenance treatment of bipolar I disorder: a double-­blind, placebo-­controlled discontinuation study. J Am Acad Child Adolesc Psychiatry 2019; 58:­287–­296.e284.

Prescribing in children and adolescents CHAPTER 5 32. Masi G, et al. Lithium treatment in bipolar adolescents: a follow-­up naturalistic study. Neuropsychiatr Dis Treat 2018; 14:­2749–­2753. 33. Wagner KD, et al. A double-­blind, randomized, placebo-­controlled trial of divalproex extended-­release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 2009; 48:­519–­532. 34. Wagner KD, et al. A double-­blind, randomized, placebo-­controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163:­1179–­1186. 35. Tohen M, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164:­1547–­1556. 36. DelBello MP, et al. A double-­blind placebo-­controlled pilot study of topiramate in manic adolescents treated with olanzapine. J Child Adolesc Psychopharmacol 2023; 33:­126–­133. 37. Haas M, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-­blind, placebo-­controlled study. Bipolar Disord 2009; 11:­687–­700. 38. Geller B, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 2012; 69:­515–­528. 39. Walkup JT, et al. Treatment of early-­age mania: outcomes for partial and nonresponders to initial treatment. J Am Acad Child Adolesc Psychiatry 2015; 54:­1008–­1019. 40. Kowatch RA, et al. Placebo-­controlled trial of valproic acid versus risperidone in children 3-­7 years of age with bipolar I disorder. J Child Adolesc Psychopharmacol 2015; 25:­306–­313. 41. Pathak S, et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-­week, double-­ blind, placebo-­controlled trial. J Clin Psychiatry 2013; 74:­e100–­e109. 42. Delbello MP, et al. A double-­blind, randomized, placebo-­controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41:­1216–­1223. 43. Delbello MP, et al. A double-­blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45:­305–­313. 44. Findling RL, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-­blind, placebo-­controlled study. J Clin Psychiatry 2009; 70:­1441–­1451. 45. Findling RL, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-­week, randomized, placebo-­controlled study. Bipolar Disord 2013; 15:­138–­149. 46. Findling RL, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-­controlled efficacy and long-­term open-­extension study. J Child Adolesc Psychopharmacol 2013; 23:­531–­544. 47. Findling RL, et al. Efficacy, safety, and tolerability of flexibly dosed ziprasidone in children and adolescents with mania in bipolar I disorder: a randomized placebo-­controlled replication study. J Child Adolesc Psychopharmacol 2022; 32:­143–­152. 48. Findling RL, et al. Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:­1032–­1041. 49. Detke HC, et al. Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-­blind, placebo-­controlled trial. J Am Acad Child Adolesc Psychiatry 2015; 54:­217–­224. 50. Loebel A, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-­blind, placebo-­controlled study. Am J Psychiatry 2014; 171:­160–­168. 51. Suppes T, et al. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-­controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res 2016; 78:­86–­93. 52. Suppes T, et  al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-­blind, placebo-­ controlled study. Am J Psychiatry 2016; 173:­400–­407. 53. Goldman R, et al. Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-­week, randomized placebo-­controlled study. J Child Adolesc Psychopharmacol 2017; 27:­516–­525. 54. Solmi M, et al. Safety of 80 antidepressants, antipsychotics, anti-­attention-­deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-­review of 78 adverse effects. World Psychiatry 2020; 19:­214–­232. 55. Delbello MP, et al. A double-­blind, placebo-­controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009; 11:­483–­493. 56. Findling RL, et al. Efficacy and safety of extended-­release quetiapine fumarate in youth with bipolar depression: an 8 week, double-­blind, placebo-­controlled trial. J Child Adolesc Psychopharmacol 2014; 24:­325–­335. 57. Suttajit S, et al. Quetiapine for acute bipolar depression: a systematic review and meta-­analysis. Drug Des Devel Ther 2014; 8:­827–­838. 58. Bridge JA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-­ analysis of randomized controlled trials. JAMA 2007; 297:­1683–­1696. 59. Calabrese JR, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-­blind, placebo-­controlled clinical trials. Bipolar Disord 2008; 10:­323–­333. 60. Findling RL, et al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-­controlled, randomized withdrawal study. J Am Acad Child Adolesc Psychiatry 2015; 54:­1020–­1031.e1023.

No comments to display

Back to top